GlassScriptPhysician profile
Sanjiv Sharma
NPI 1336342138
$5,031.03
in general payments reported to CMS, 2019-2025
36 companies · $227 in 2025
The $227 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,496 · 2020: $369 · 2021: $1,366 · 2022: $538 · 2023: $476 · 2024: $559 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,261.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $988.05 | 2019-2021 | |
| Amgen INC. | $668.95 | 2019-2025 | Repatha |
| Abbott Laboratories | $437.53 | 2019-2025 | Merlin@Home, Xience Skypoint |
| Merck Sharp & Dohme LLC | $394.07 | 2021-2025 | Verquvo |
| Abiomed | $318.30 | 2019 | |
| Penumbra, INC. | $227.62 | 2024 | Indigo System, Ruby Coil |
| Novartis Pharmaceuticals Corporation | $213.48 | 2019-2025 | |
| Cvrx, INC. | $177.11 | 2022-2023 | Barostim Neo System |
| Amarin Pharma, INC. | $152.63 | 2019 | |
| Getinge USA Sales, LLC | $149.78 | 2020 | |
| Pfizer INC. | $142.87 | 2019-2024 | |
| Boston Scientific Corporation | $141.14 | 2019-2021 | |
| Medtronic Vascular, INC. | $123.64 | 2019 | |
| Medtronic, INC. | $94.84 | 2024-2025 | In.Pact Admiral, Symplicity G3, Turbohawk |
| Scpharmaceuticals INC. | $90.92 | 2024-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $76.92 | 2021-2023 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $75.89 | 2022-2025 | Wainua, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.41 | 2019-2021 | |
| Irhythm Technologies, INC. | $61.99 | 2022-2023 | Zio Xt Patch |
| Alnylam Pharmaceuticals INC. | $61.00 | 2019-2022 | |
| Gilead Sciences, INC. | $56.92 | 2019 | |
| Sanofi-Aventis U.S. LLC | $38.67 | 2019 | |
| Cathworks, INC. | $35.99 | 2019 | |
| Akcea Therapeutics, INC. | $35.10 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $31.96 | 2022-2023 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $24.44 | 2024 | |
| Cardiva Medical, INC. | $21.95 | 2020 | |
| Cook Medical LLC | $20.10 | 2023 | Performer |
| Kowa Pharmaceuticals America, INC. | $18.87 | 2019 | |
| Daiichi Sankyo INC. | $17.74 | 2023 | Injectafer |
| Kiniksa Pharmaceuticals International, Plc | $17.06 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $15.36 | 2023 | Camzyos |
| Lupin INC. | $13.32 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.62 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.79 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjiv Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.